CD274 and lymphangioleiomyomatosis: Anti-PD1/PD-L1 and anti-CTLA-4 therapies were shown to enhance survival in mouse models of LAM (17,18), suggesting that countering immunosuppression in LAM could be an effective strategy for treating LAM.